Skip to main content
Hugel, Inc. logo

Hugel, Inc. — Investor Relations & Filings

Ticker · 145020 ISIN · KR7145020004 KO Manufacturing
Open in API
Filings indexed 499 across all filing types
Latest filing 2023-03-22 Annual Report
Country KR South Korea
Listing KO 145020

About Hugel, Inc.

https://www.hugel-inc.com/

Hugel, Inc. is a global biopharmaceutical company specializing in the medical aesthetics and therapeutics market. The company develops, manufactures, and distributes a portfolio of high-quality products, including its flagship botulinum toxin type A formulations, known commercially as Botulax and Letybo. Its product line also features a range of hyaluronic acid (HA) fillers and PDO threads. Recognized as a leader in its field, Hugel is focused on providing innovative, efficient, and proven solutions to medical professionals worldwide. The company is committed to advancing aesthetic medicine through continuous research and development to create effective and reliable treatments.

Recent filings

Filing Released Lang Actions
[기재정정]사업보고서 (2022.12)
Annual Report Classification · 100% confidence The document is a '사업보고서' (Business Report) for Hugel, Inc., which is the Korean equivalent of an Annual Report (10-K). It contains comprehensive financial statements, management discussion and analysis, governance information, and auditor opinions for the fiscal year 2022. It is a full-length regulatory filing, not an announcement or a summary. FY 2022
2023-03-22 Korean
투자판단관련주요경영사항(리도카인 함유 액상 보툴리눔 톡신 제제 "HG102" 임상3상 IND 신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Hugel regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically the submission of an Investigational New Drug (IND) application for a Phase 3 clinical trial of their product 'HG102'. This is a standard corporate disclosure of a material event related to business operations and R&D progress. Since it does not fit into specific categories like financial reports, dividends, or director dealings, it falls under the general regulatory filing category.
2023-03-16 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Hugel Inc. It contains the meeting agenda, voting procedures, and detailed management information including board activity reports, director remuneration, and business overviews. While it contains management information, the primary purpose of this specific document is to formally notify shareholders of the upcoming Annual General Meeting (AGM) and provide the necessary materials for that meeting. Therefore, it is classified as AGM Information.
2023-03-15 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted by Hugel Co., Ltd. regarding the scheduling of its Annual General Meeting (AGM) on a 'concentrated date' (a date when many companies hold their AGMs). It explains the internal and external reasons for choosing this date and acknowledges the company's status regarding the 'Shareholder Meeting Dispersion Voluntary Compliance Program'. Since this is a regulatory disclosure regarding meeting logistics rather than the meeting materials themselves or a report publication announcement, it falls under the general regulatory filing category.
2023-03-15 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (Proxy Solicitation Statement). It contains information regarding the upcoming Annual General Meeting (AGM), including the purpose of the meeting, voting procedures (electronic/written), and details on the agenda items such as financial statement approval. This document is specifically designed to solicit proxies from shareholders for the AGM, fitting the definition of a Proxy Solicitation & Information Statement.
2023-03-15 Korean
투자판단관련주요경영사항('보톡스 의약품을 미승인 판매한 6개 제약사 기소' 검찰 보도 관련사항)
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory disclosure regarding a legal proceeding (prosecution of the company and its employees for alleged violations of the Pharmaceutical Affairs Act). It is a short, specific disclosure of a legal event, which fits the definition of a Legal Proceedings Report (LTR).
2023-03-15 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.